May 11, 2004
GW Pharmaceuticals Plc, a U.K. company developing cannabis-based drugs, said it asked Canadian regulators to approve its pain-killing spray Sativex.
Sativex would be marketed in Canada by Bayer AG, Germany's second-biggest drug and chemical maker, the company said in a Regulatory News Service release.
Sativex is the unprofitable company's product closest to the market. GW Pharmaceuticals is waiting for U.K. regulators to approve the drug. Last month, the company said it expected a third delay to U.K. regulatory approval and will give an update on the expected timeline in June.
GW Pharmaceuticals has asked regulators to approve Sativex for use against
pain in multiple sclerosis patients, and also to treat neuropathic pain,
which is caused by a diseased or damaged nervous system.
Copyright © 2004, Bloomberg